Information  X 
Enter a valid email address

Medica Group PLC (MGP)

  Print   

Friday 27 May, 2022

Medica Group PLC

Notice of AGM

RNS Number : 1494N
Medica Group PLC
27 May 2022
 

27 May 2022

 

Medica Group Plc

 

Notice of AGM

 

Medica Group Plc (LSE:MGP, the "Company" ), the UK market leader by revenue in the provision of teleradiology services, announces that, f urther to the publication on 12 April 2022 of the Company's Annual Report and Accounts for the year ended 31 December 2021, the Company has today posted or made available to shareholders the 2022 Notice of Annual General Meeting (the "Notice of AGM") and related form of proxy.

 

Electronic copies of these documents are available on the Company's website at

www.medicagroupplc.com/investors/results-and-reports

 

A copy of the Notice of AGM will be submitted to the National Storage Mechanism and be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

The AGM will be held on 27 June 2022 at 11.00am at the offices of DLA Piper at 160 Aldersgate Street, London, EC1A 4HT.

 

 

For further information, please contact:  

 

Medica Group Plc:

Stuart Quin, Chief Executive Officer

Richard Jones, Chief Financial Officer

 

+44 (0)33 33 111 222

 

FTI Consulting

Victoria Foster Mitchell

Sam Purewal

 

 

+44 (0)20 3727 1000

Liberum (Joint Broker)

Phil Walker

Richard Lindley

 

+44 (0)20 3100 2000

Numis (Joint Broker)

Freddie Barnfield

Duncan Monteith

Euan Brown

 

+44 (0)20 7260 1000

 

 

About Medica Group PLC

 

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

 

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition,  Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

 

The Company currently offers two primary services to hospital radiology departments:

 

·   NightHawk - urgent reporting service

·   Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

 

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

 

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit:  www.medicagroupplc.com  

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAEAKSXAAEAEFA

a d v e r t i s e m e n t